Feature Review Papers in Acquired Cardiovascular Disease

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Acquired Cardiovascular Disease".

Deadline for manuscript submissions: closed (1 February 2024) | Viewed by 3728

Special Issue Editor

Acute Cardiac Care Unit, Cardiology Department, Vall d'Hebron University Hospital and Research Institute, Autonomous University of Barcelona, 08035 Barcelona, Spain
Interests: acute coronary syndromes; ischemic heart disease; platelet-induced microvascular damage; acute cardiac care

Special Issue Information

Dear Colleagues,

The knowledge on the pathophysiology, diagnosis, and treatment of acquired cardiovascular diseases is continuously evolving at a rapid pace. This makes that health professionals often find it difficult to stay up to date, not only about the most recent advances in general cardiovascular sciences but also about those related to their specific areas of interest. To help mitigate this, JCDD is launching the Special Issue ‘Feature Review Papers in Acquired Cardiovascular Disease’. This issue is aimed to provide the readers with a summary of the most significant contributions that have appeared recently in this field. Prestigious scientists and clinicians will be invited to submit high-quality review papers on the different areas of acquired cardiovascular disease, from bench to bedside.

Dr. José A. Barrabés
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acquired cardiovascular disease
  • coronary artery disease
  • peripheral vascular disease
  • heart failure
  • artificial intelligence
  • genetics
  • cell therapy
  • cardiovascular imaging
  • atherosclerosis
  • ischemic heart disease
  • valvular heart disease
  • arrhythmias
  • cardiomyopathies
  • cardio-oncology
  • interventional cardiology
  • cardiovascular surgery
  • mechanical circulatory support

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 733 KiB  
Review
Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
J. Cardiovasc. Dev. Dis. 2023, 10(9), 388; https://doi.org/10.3390/jcdd10090388 - 08 Sep 2023
Cited by 1 | Viewed by 1537
Abstract
Heart failure with reduced ejection fraction is a chronic and progressive syndrome that continues to be a substantial financial burden for health systems in Western countries. Despite remarkable advances in pharmacologic and device-based therapy over the last few years, patients with heart failure [...] Read more.
Heart failure with reduced ejection fraction is a chronic and progressive syndrome that continues to be a substantial financial burden for health systems in Western countries. Despite remarkable advances in pharmacologic and device-based therapy over the last few years, patients with heart failure with reduced ejection fraction have a high residual risk of adverse outcomes, even when treated with optimal guideline-directed medical therapy and in a clinically stable state. Worsening heart failure episodes represent a critical event in the heart failure trajectory, carrying high residual risk at discharge and dismal short- or long-term prognosis. Recently, vericiguat, a soluble guanylate cyclase stimulator, has been proposed as a novel drug whose use is already associated with a reduction in heart failure-related hospitalizations in patients in guideline-directed medical therapy. In this review, we summarized the pathophysiology of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate cascade in patients with heart failure with reduced ejection fraction, the pharmacology of vericiguat as well as the evidence regarding their use in patients with HFrEF. Finally, tips and tricks for its use in standard clinical practice are provided. Full article
(This article belongs to the Special Issue Feature Review Papers in Acquired Cardiovascular Disease)
Show Figures

Graphical abstract

14 pages, 1189 KiB  
Review
Arrhythmias in Patients with Cardiac Amyloidosis: A Comprehensive Review on Clinical Management and Devices
J. Cardiovasc. Dev. Dis. 2023, 10(8), 337; https://doi.org/10.3390/jcdd10080337 - 05 Aug 2023
Cited by 3 | Viewed by 1859
Abstract
Cardiac amyloidosis (CA) is a rare but potentially life-threatening disease in which misfolded proteins accumulate in the cardiac wall tissue. Heart rhythm disorders in CA, including supraventricular arrhythmias, conduction system disturbances, or ventricular arrhythmias, play a major role in CA morbidity and mortality, [...] Read more.
Cardiac amyloidosis (CA) is a rare but potentially life-threatening disease in which misfolded proteins accumulate in the cardiac wall tissue. Heart rhythm disorders in CA, including supraventricular arrhythmias, conduction system disturbances, or ventricular arrhythmias, play a major role in CA morbidity and mortality, and thus require supplementary management. Among them, AF is the most frequent arrhythmia during CA hospitalizations and is associated with significantly higher mortality, while ventricular arrhythmias are also common and are usually associated with poor prognosis. Early diagnosis of potential arrythmias could be performed through ECG, Holter monitoring, and/or electrophysiology study. Clinical management of these patients is quite significant, and it usually includes initiation of amiodarone and/or digoxin in patients with AF, potential electrical cardioversion, or ablation in specific patients with indication, as well as initiation of anticoagulants in all patients, independent of AF and CHADS-VASc score, for potential intracardiac thrombus. Moreover, identification of patients with conduction disorders that could benefit from prophylactic pacemaker implantation and/or CRT as well as identification of patients with life-threatening ventricular arrythmias that could benefit from ICD could both increase the survival rates of these patients and improve their quality of life. Full article
(This article belongs to the Special Issue Feature Review Papers in Acquired Cardiovascular Disease)
Show Figures

Figure 1

Back to TopTop